Skip to main content

Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations.

Publication ,  Journal Article
Younossi, ZM; Noureddin, M; Bernstein, D; Kwo, P; Russo, M; Shiffman, ML; Younes, Z; Abdelmalek, M
Published in: The American journal of gastroenterology
February 2021

Nonalcoholic fatty liver disease (NAFLD) is generally considered a silent and potentially reversible condition. The subtype of NAFLD that can be classified as nonalcoholic steatohepatitis (NASH) can progress to advanced fibrosis and cirrhosis. Because of the metabolic nature of the pathogenic mechanism underlying NAFLD and NASH, it is often accompanied by common comorbidities such as obesity, insulin resistance, and type 2 diabetes mellitus. The increase in the prevalence of these comorbidities has resulted in a parallel increase in the prevalence of NAFLD and NASH, globally, nationally, and even in children. In recent years, it has been identified that the stage of fibrosis is the most important predictor of liver outcomes; therefore, identifying patients with NAFLD and NASH with more advanced stages of fibrosis can be essential for optimal management. Several noninvasive tools for diagnosing and staging NAFLD and NASH are available, but simple and straightforward recommendations on the use of these tools are not. Recognizing these unmet needs, hepatologists who are members of the American College of Gastroenterology and the Chronic Liver Disease Foundation created a practical decision tree/algorithm to risk stratify NAFLD/NASH as a resource in gastroenterology/hepatology clinical practices. This review will provide insight into how this algorithm was developed, describe it in detail, and provide recommendations for its use in clinical practice.

Altmetric Attention Stats
Dimensions Citation Stats

Published In

The American journal of gastroenterology

DOI

EISSN

1572-0241

ISSN

0002-9270

Publication Date

February 2021

Volume

116

Issue

2

Start / End Page

254 / 262

Related Subject Headings

  • Tissue Inhibitor of Metalloproteinase-1
  • Serum Albumin
  • Risk Assessment
  • Procollagen
  • Practice Guidelines as Topic
  • Platelet Count
  • Peptide Fragments
  • Obesity
  • Non-alcoholic Fatty Liver Disease
  • Magnetic Resonance Imaging
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Younossi, Z. M., Noureddin, M., Bernstein, D., Kwo, P., Russo, M., Shiffman, M. L., … Abdelmalek, M. (2021). Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations. The American Journal of Gastroenterology, 116(2), 254–262. https://doi.org/10.14309/ajg.0000000000001054
Younossi, Zobair M., Mazen Noureddin, David Bernstein, Paul Kwo, Mark Russo, Mitchell L. Shiffman, Ziad Younes, and Manal Abdelmalek. “Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations.The American Journal of Gastroenterology 116, no. 2 (February 2021): 254–62. https://doi.org/10.14309/ajg.0000000000001054.
Younossi ZM, Noureddin M, Bernstein D, Kwo P, Russo M, Shiffman ML, et al. Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations. The American journal of gastroenterology. 2021 Feb;116(2):254–62.
Younossi, Zobair M., et al. “Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations.The American Journal of Gastroenterology, vol. 116, no. 2, Feb. 2021, pp. 254–62. Epmc, doi:10.14309/ajg.0000000000001054.
Younossi ZM, Noureddin M, Bernstein D, Kwo P, Russo M, Shiffman ML, Younes Z, Abdelmalek M. Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations. The American journal of gastroenterology. 2021 Feb;116(2):254–262.

Published In

The American journal of gastroenterology

DOI

EISSN

1572-0241

ISSN

0002-9270

Publication Date

February 2021

Volume

116

Issue

2

Start / End Page

254 / 262

Related Subject Headings

  • Tissue Inhibitor of Metalloproteinase-1
  • Serum Albumin
  • Risk Assessment
  • Procollagen
  • Practice Guidelines as Topic
  • Platelet Count
  • Peptide Fragments
  • Obesity
  • Non-alcoholic Fatty Liver Disease
  • Magnetic Resonance Imaging